Pharmacologic neuromodulation for bloating.

IF 1.7 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Scandinavian Journal of Gastroenterology Pub Date : 2025-09-01 Epub Date: 2025-08-08 DOI:10.1080/00365521.2025.2544306

Elizabeth N Madva, Sanskriti Varma, Victoria Small, Mia Dekel, Silvia Salamone, Helen Burton-Murray, Braden Kuo, Kyle Staller

{"title":"Pharmacologic neuromodulation for bloating.","authors":"Elizabeth N Madva, Sanskriti Varma, Victoria Small, Mia Dekel, Silvia Salamone, Helen Burton-Murray, Braden Kuo, Kyle Staller","doi":"10.1080/00365521.2025.2544306","DOIUrl":null,"url":null,"abstract":"Background: Though bloating is a common and highly distressing symptom among patients with disorders of gut-brain interaction (DGBI), few targeted treatment options exist. In this study, we examined the use and efficacy of pharmacologic neuromodulators to treat bloating specifically.Methods: In a retrospective study of consecutively referred patients with a DGBI (N = 77; ages 18-74, 87% female) to a tertiary neurogastroenterology clinic who were prescribed a neuromodulator for a primary complaint of bloating in 2016-2022, the degree of patient-reported bloating response (0-100%) to the maximum dose of a prescribed neuromodulator was examined using multivariable logistic regression, adjusted for key covariates.Results: Forty-seven (61.0%) patients reported any response (>0%) to neuromodulation and 28 (36.4%) met the a priori responder definition (≥50% improvement). Duloxetine was the most commonly prescribed neuromodulator (n = 52, 67.5%). On multivariable analysis, only younger age was associated with an increased odds of neuromodulator response (OR 1.04, 95% CI [1.08, 1.01]).Conclusions: Pharmacologic neuromodulators may show promise as a tool for the treatment of bloating, and further research is warranted.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"874-878"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00365521.2025.2544306","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Though bloating is a common and highly distressing symptom among patients with disorders of gut-brain interaction (DGBI), few targeted treatment options exist. In this study, we examined the use and efficacy of pharmacologic neuromodulators to treat bloating specifically.

Methods: In a retrospective study of consecutively referred patients with a DGBI (N = 77; ages 18-74, 87% female) to a tertiary neurogastroenterology clinic who were prescribed a neuromodulator for a primary complaint of bloating in 2016-2022, the degree of patient-reported bloating response (0-100%) to the maximum dose of a prescribed neuromodulator was examined using multivariable logistic regression, adjusted for key covariates.

Results: Forty-seven (61.0%) patients reported any response (>0%) to neuromodulation and 28 (36.4%) met the a priori responder definition (≥50% improvement). Duloxetine was the most commonly prescribed neuromodulator (n = 52, 67.5%). On multivariable analysis, only younger age was associated with an increased odds of neuromodulator response (OR 1.04, 95% CI [1.08, 1.01]).

Conclusions: Pharmacologic neuromodulators may show promise as a tool for the treatment of bloating, and further research is warranted.

查看原文本刊更多论文

腹胀的药理神经调节。

背景：虽然腹胀是肠-脑相互作用障碍（DGBI）患者常见且非常痛苦的症状，但很少有针对性的治疗方案存在。在这项研究中，我们检查了药理学神经调节剂治疗腹胀的使用和疗效。方法：回顾性研究连续转诊的DGBI患者(N = 77；年龄在18-74岁（87%为女性）的患者，在2016-2022年期间因腹胀主因服用神经调节剂，来到第三神经胃肠病学诊所，使用多变量logistic回归检查患者报告的对最大剂量神经调节剂的腹胀反应程度（0-100%），并对关键协变量进行调整。结果：47例（61.0%）患者报告对神经调节有任何反应（>0%），28例（36.4%）患者符合先验应答定义（改善≥50%）。度洛西汀是最常用的神经调节剂（n = 52, 67.5%）。在多变量分析中，只有更年轻的年龄与神经调节剂反应的几率增加有关（OR 1.04, 95% CI[1.08, 1.01]）。结论：药理学神经调节剂有望成为治疗腹胀的一种工具，值得进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Scandinavian Journal of Gastroenterology 医学-胃肠肝病学

CiteScore

3.40

自引率

5.30%

发文量

222

审稿时长

3-8 weeks

期刊介绍： The Scandinavian Journal of Gastroenterology is one of the most important journals for international medical research in gastroenterology and hepatology with international contributors, Editorial Board, and distribution